Home Cart Sign in  
Chemical Structure| 1431326-61-2 Chemical Structure| 1431326-61-2

Structure of ORY-1001
CAS No.: 1431326-61-2

Chemical Structure| 1431326-61-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ORY-1001 is a selective inhibitor of lysine-specific demethylase LSD1/KDM1A with IC50 of < 20 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ORY-1001

CAS No. :1431326-61-2
Formula : C15H24Cl2N2
M.W : 303.27
SMILES Code : NC1CCC(N[C@H]2[C@H](C3=CC=CC=C3)C2)CC1.[H]Cl.[H]Cl
MDL No. :MFCD28900684
InChI Key :UCINOBZMLCREGM-RNNUGBGQSA-N
Pubchem ID :71664305

Safety of ORY-1001

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ORY-1001

epigenetics

Isoform Comparison

Biological Activity

Target
  • KDM1

    LSD1, IC50:20 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
H1299 cells 80 and 160 µM 1, 2, 3, and 4 days ORY-1001 significantly inhibited cell proliferation PMC6290890
A549 cells 80 and 160 µM 1, 2, 3, and 4 days ORY-1001 significantly inhibited cell proliferation PMC6290890
BEAS-2B cells 80 and 160 µM 1, 2, 3, and 4 days ORY-1001 did not significantly affect normal cell proliferation PMC6290890
NCI-H510A 0.002 to 2000 nM 10 days Assessed the impact on cell viability, showing that ORY-1001 exhibited subnanomolar antiproliferative activity in NCI-H510A cells. PMC8669716
MV(4;11) 2000, 200, 20, and 2 nM 24 hours Assessed LSD1 target engagement, showing that ORY-1001 achieved high LSD1 target engagement at all concentrations tested. PMC8669716
A549 cells 50 nM 24 hours ORY-1001 inhibits KDM1A, leading to accumulation of H3K9 methylation and loss of H3K9 acetylation PMC10182654
U2OS cells 50 nM 24 hours ORY-1001 inhibits KDM1A, leading to accumulation of H3K9 methylation and loss of H3K9 acetylation PMC10182654
FHSC04 1nM 48 hours ORY-1001 treatment led to changes in NOTCH1, REST, and ASCL1 transcription and protein expression, with increased cell death. PMC6530478
BT-474 cells 10 μM 48 hours To evaluate the effect of iadademstat on SOX2 enhancer-driven transcriptional activation in BT-474 cells, results showed that iadademstat dose-dependently suppressed the transcriptional activation of SOX2 PMC7138538
MGC-803 5 μM 5 days Induced accumulation of H3K4me1/2 and H3K9me1/2, inhibited gastric cancer cell migration PMC8084583
BGC-823 5 μM 5 days Induced accumulation of H3K4me1/2 and H3K9me1/2, inhibited gastric cancer cell migration PMC8084583
MDA-MB-436 cells 3.98 μM 6 days To evaluate the effect of iadademstat on mammosphere formation in MDA-MB-436 cells, results showed that iadademstat dose-dependently reduced the number of mammospheres PMC7138538
TF-1a 0.002 to 2000 nM 96 hours Assessed the impact on cell viability, showing that ORY-1001 exhibited subnanomolar antileukemic activity in TF-1a cells. PMC8669716
THP-1 0.02 to 2000 nM 96 hours Assessed the induction of CD11b protein levels, showing that ORY-1001 significantly induced CD11b expression in THP-1 cells. PMC8669716
NCI-H510A 10nM 96 hours ORY-1001 treatment resulted in 1400 differentially expressed genes (FDR<0.05), with enrichment in NOTCH pathway genes and decreased expression of ASCL1. PMC6530478
MV(4;11) cells 5 nM 96 hours the free KDM1A fraction was reduced by ~80% PMC6527171
THP-1 cells 25 nM completely prevented pull-down of KDM1A PMC6527171

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice TC-1 subcutaneous xenograft model Intraperitoneal injection 50 mg/kg Three times per week for 3-4 weeks To evaluate the inhibitory effect of ORY-1001 combined with anti-CD47/PD-L1 monoclonal antibodies on tumor growth. The results showed that the combination of ORY-1001 and anti-CD47/PD-L1 monoclonal antibodies significantly inhibited tumor growth more effectively than a single blockade strategy. PMC7969769
NSG mice SCLC PDX models Oral 400μg/kg once weekly for 21 days ORY-1001 showed tumor inhibitory effects in all six of the ASCL1-positive PDX models tested, with complete and durable tumor regression observed in the FHSC04 model. PMC6530478

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.30mL

0.66mL

0.33mL

16.49mL

3.30mL

1.65mL

32.97mL

6.59mL

3.30mL

References

 

Historical Records

Categories